Biogen is pushing its experimental Alzheimer’s drug diranersen into Phase 3 trials despite missing the primary dose-response goal in its 416-patient CELIA study, after the lowest tested dose paradoxically delivered the strongest results—slowing cognitive decline on the CDR-SB scale by 26% over 18 months.

UNLV researchers are working with former football players and professional fighters to track head injuries and brain damage. 

Transferrin Receptor Hijacking Delivers a 1,000-Fold Brain Exposure Leap for Oligonucleotides

The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.

The extended-release oral combination of dextromethorphan-bupropion uses a different mechanism of action than antipsychotic medications, which clinicians sometimes prescribe for patients with Alzheimer's disease who also experience agitation. But whether the new medication will be used as a first-line treatment is up for debate.

More than seven years of development, over $60 million in funding and a series of early clinical studies have led to this: Allyx Therapeutics is preparing for what may be the most consequential test in the New Haven-based biotech startup’s history.

Anti-amyloid drugs have transformed the Alzheimer’s disease (AD) treatment landscape, marking the first time clinicians have had access to disease-modifying treatments. Yet their use is limited to a relatively small subset of patients with early symptomatic disease.

Out now is the 10th annual Alzheimer's Drug Development Pipeline Report.